Gilead Sciences
Q3 2022 Earnings Call
Oct 27, 2022, 4:30 p.m. ET
Contents:
- Prepared Remarks
- Questions and Answers
- Call Participants
Prepared Remarks:
Operator
Ladies and gentlemen, thank you for your patience and thank you for attending today's third quarter 2022 Gilead Sciences earnings conference call. My name is Amber, and I will be your operator for today's call. [Operator instructions]. It is now my pleasure to hand the conference over to our host, Jacquie Ross, VP of investor relations.
Jacquie, please proceed.
Jacquie Ross -- Vice President, Investor Relations
Thank you, operator, and good afternoon, everyone. Just after the market close today, we issued a press release with earnings results for the third quarter of 2022. The press release, slides, and supplementary data are available on the investors' section of our website at gilead.com. The speakers on today's call will be our chairman and chief executive officer, Daniel O'Day; our chief commercial officer, Johanna Mercier; our chief medical officer, Merdad Parsey; and our chief financial officer, Andrew Dickinson.
After that, we'll open up the call to Q&A where the team will be joined by Christi Shaw, the chief executive officer of Kite. Before we get started, let me remind you that we will be making forward-looking statements, including those related to Gilead's business financial condition and results of operations, plans, and expectations with respect to products, product candidates, corporate strategy, business and operations, financial projections and the use of capital and 2022 financial guidance, all of which involve certain assumptions, risks, and uncertainties that are beyond our control and could cause actual results to differ materially from these statements. A description of these risks can be found in the earnings press release and our latest SEC disclosure documents. All forward-looking statements are based on information currently available to Gilead, and Gilead assumes no obligation to update any such forward-looking statements.
Non-GAAP financial measures will be used to help you understand the company's underlying business performance. The GAAP to non-GAAP reconciliations are provided in the earnings press release and our supplemental data sheet as well as on the Gilead website. Now I'll turn the call over to Dan.
Dan O'Day -- Chairman and Chief Executive Officer
Thank you, Jacquie, and good afternoon, everybody. We're pleased to connect with all of you today to share the details of another very strong quarter. Thanks to strong commercial and clinical execution by our teams, the positive momentum continues to build. Total product sales, excluding Veklury, were $6.1 billion, growing 6% sequentially and 11% year-over-year.